Imugene Managing Director and Chief Executive Officer Leslie Chong said, “Clinicians at the
trial sites observed no toxicities and report all vaccinated patients developed immune responses
and antibodies to the HER-2 protein which encourages cancer growth. We look forward to
reporting on further milestones and completing the analysis in the coming months.”
This is an encouraging statement from Leslie
Imugene Managing Director and Chief Executive Officer Leslie...
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
-0.003(5.08%) |
Mkt cap ! $411.5M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.5¢ | $2.898M | 51.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 4186955 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 337877 | 2 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |